Work reintegration in patients treated for diabetic macular edema
Main Article Content
Keywords
Diabetic Retinopathy, Macular Edema, Drug, Anti-Angiogenic
Abstract
Abstract
Background: Type 2 diabetes mellitus (T2DM) has increased in prevalence, and with it, complications such as diabetic retinopathy and diabetic macular edema (DME), which cause disability due to visual impairment and high medical and social costs, as it is the leading cause of blindness in the economically active population aged 18 to 64. Intravitreal anti-angiogenic (anti-VEGF) therapy is the first line of treatment.
Objective: To estimate the proportion of patients with DME who return to work and the time required after treatment.
Material and methods: Based on literature and local data with a response rate ≥ 60%, an observational study was planned; the analysis was descriptive, and the post-intervention comparison was performed using the chi-square test.
Results: 45 patients were included (26 women, 19 men; 57.4 ± 5.0 years; T2DM duration 16 [12-20] years), with diabetic retinopathy and macular edema: proliferative 53.3%, mild non-proliferative 22.2%, severe 17.8%, moderate 6.7%. Functional success (visual acuity, [VA] ≥ 0.5) was achieved in 70% of mild non-proliferative cases and 25% of proliferative/severe cases. Mean gain in decimal VA was + 0.127 RE and + 0.090 LE. A total of 33.3% reached VA ≥ 0.5 after loading doses, a functional level compatible with reading and precision tasks. An inverse correlation was observed between central macular thickness and final VA.
Conclusions: Early intervention maximized the benefit with intravitreal anti-VEGF, improving function and anatomy in DME. A significant proportion of patients of working age returned to work, reducing days of disability and improving quality of life.
References
1. Wang W, Lo ACY. Diabetic retinopathy: Pathophysiology and treatments. Int J Mol Sci [Internet]. 2018;19(6). doi: 10.3390/ijms19061816
2. Bourne R, Steinmetz JD, Flaxman S, et al. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e130-43. doi: 10.1016/s2214-109x(20)30425-3
3. Organización Mundial de la Salud. Ceguera y discapacidad visual. 2022. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/blindness-and-visual-impairment
4. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal Aflibercept for diabetic macular edema. Ophthalmology. 2016;123(11):2376-85. doi: 10.1016/j.ophtha.2016.07.032
5. Kim EJ, Lin WV, Rodriguez SM, et al. Treatment of diabetic macular edema. Curr Diab Rep. 2019;19(9):68. doi: 10.1007/s11892-019-118
6. Mekjavić PJ, Balčiūnienė VJ, Ćeklić L, et al. The burden of macular diseases in central and eastern Europe: implications for healthcare systems. Value Health Reg Issues. 2019;19:1-6. doi: 10.1016/j.vhri.2018.11.002
7. Daien V, Eldem BM, Talks JS, et al. Real-world data in retinal diseases treated with anti-vascular endothelial growth factor therapy: a systematic approach to identify and characterize data sources. BMC Ophthalmol. 2019;19(1). doi: 10.1186/s12886-019-1208-9
8. Kuroiwa DAK, Malerbi FK, Regatieri CVS. New insights in resistant diabetic macular edema. Ophthalmologica. 2021;244(6):485-94. doi: 10.1159/000516614
9. Lin KY, Hsih WH, Lin YB, et al. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12(8):1322-5. doi: 10.1111/jdi.13480
10. Ke KM, Montgomery AM, Stevenson M, et al. Formal and informal care utilisation amongst elderly persons with visual impairment. Br J Ophthalmol. 2007;91(10):1279-81. doi: 10.1136/ bjo.2006.113142
11. World Health Organization. World report on vision. Geneva: WHO; 2019.
12. Pan American Health Organization. Visual health. Washington (DC): PAHO; [sin fecha de publicación]. Disponible en: https://www.paho.org/
13. California Department of Motor Vehicles. Vision impairment and DMV requirements. Sacramento, CA: California Department of Motor Vehicles; [sin fecha de publicación]. Disponible en: https://www.dmv.ca.gov/portal/driver-education-and-safety/medical-conditions-and-driving/vision-conditions/
14. Secretaría de Salud. Norma Oficial Mexicana NOM-035-SSA3-2012, En materia de información en salud. México: Diario Oficial de la Federación; 30 de noviembre de 2012. Disponible en: https://dof.gob.mx/nota_detalle.php?codigo=5280848&fecha=30/11/2012
15. American Academy of Ophthalmology; EyeWiki. Driving restrictions per state. San Francisco, CA: American Academy of Ophthalmology; 2025. Disponible: https://eyewiki.org/Driving_Restrictions_per_State
16. Liberski S, Wichrowska M, Kociecki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. 2022;23:9424. doi: 10.3390/ijms23169424
17. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039
18. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034
19. Boyer DS, Nguyen QD, Brown DM; RIDE and RISE Research Group. Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology. 2015;122(12):2504-13.e1. doi: 10.1016/j.ophtha.2015.08.006
20. Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-203. doi: 10.1056/NEJMoa1414264
21. Rodríguez FJ, Wu L, Bordon AF, et al.; AQUILA Investigators. Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study. Int J Retina Vitreous. 2022;8(1):52. doi: 10.1186/s40942-022-00396-y
22. International Council of Ophthalmology. Visual Standards: Aspects and Ranges of Vision Loss. San Francisco,CA: ICO; 2015.
23. International Council of Ophthalmology. Vision Requirements for Driving Safety. San Francisco, CA: ICO; 2016.
24. Wang P, Wang Z, Zhang S, et al. Relationship between OCT-measured central macular thickness and visual acuity in diabetic macular edema: a systematic review and meta-analysis. Int J Ophthalmol. 2022;15(2):309-18.
25. Radwan SH, Soliman AZ, Tokarev J, et al. Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmol. 2015;133(3):291-7.
26. Park J, Lee J, Shin YI, et al. Prevalence and clinical implications of subretinal fluid in retinal vascular diseases: a real-world study including diabetic macular edema. BMC Ophthalmol. 2023;23:60. doi: 10.1186/s12886-023-02749-3
27. Kalur A, Xu BY, Sridhar J, et al. Impact of retinal fluid (IRF/SRF) volumes on visual outcomes after anti-VEGF in diabetic macular edema. Can J Ophthalmol. 2023;58(4):e157-65. doi: 10.1016/j.jcjo.2022.06.013
28. Sherrod CE, Vitale S, Frick KD, et al. Association of vision loss and work status in the United States. JAMA Ophthalmol. 2014;132(10):1239-45.
29. Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMA Ophthalmol. 2016;134(8):888-96. doi: 10.1001/jamaophthalmol.2016.1669
30. Bressler NM, Beaulieu WT, Glassman AR, et al. Relationship between visual acuity and central subfield thickness changes in diabetic macular edema treated with anti-VEGF therapy. JAMA Ophthalmol. 2019;137(9):977-85.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.